Drugs / UBX-303061
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06590961 | Feb 2025 → Aug 2027 expected | lymphoid neoplasm | Ubix Therapeutics, Inc. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | UBX-303061 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06590961 ↗ |
| Route | Oral | “UBX-303061 oral dosage” NCT06590961 ↗ |